The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world utilization and safety of ipilimumab plus nivolumab (I+N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).
 
Myuran Thana
No Relationships to Disclose
 
Naveen S. Basappa
Honoraria - Astellas Pharma; Eisai; Ipsen; Janssen; Merck; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Pfizer; Roche Canada
Travel, Accommodations, Expenses - Eisai; Janssen
 
Sunita Ghosh
No Relationships to Disclose
 
Christian K. Kollmannsberger
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Novartis; Pfizer
Travel, Accommodations, Expenses - Eisai; Novartis; Pfizer
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
Jeffrey Graham
No Relationships to Disclose
 
Denis Soulieres
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ipsen; Merck; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Ipsen; Merck; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Aaron Hansen
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Merck; Pfizer
Consulting or Advisory Role - Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Merck; Novartis
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Aly-Khan A. Lalani
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche/Genentech; Tersera
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Pfizer; Roche/Genentech; Tersera
Research Funding - Bristol-Myers Squibb (Inst); Ipsen; Novartis; Roche
 
Vincent Castonguay
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Janssen; Novartis
 
M. Neil Reaume
Honoraria - AstraZeneca; Eisai; Ipsen; Merck; Novartis; Roche
Consulting or Advisory Role - Astellas Pharma; Pfizer
 
Georg A. Bjarnason
Honoraria - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
Research Funding - Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Rodney H. Breau
No Relationships to Disclose
 
Frederic Pouliot
Honoraria - Amgen; Astellas Pharma; Bayer; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Janssen; Progenics; Sanofi
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Sanofi (Inst)
Expert Testimony - Amgen; Astellas Pharma; Bayer; Sanofi
Travel, Accommodations, Expenses - Bayer; Sanofi
 
Anil Kapoor
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Ipsen; Janssen Oncology; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst)
 
Lori Wood
Research Funding - Aragon Pharmaceuticals (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche Canada (Inst)